Simvastatin (sodium salt)
mRNA synthesis
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
SYBR Safe DNA Gel Stain
Safe and sensitive stain for visualization of DNA or RNA in agarose or acrylamide gels.
Inhibitor Cocktails
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
Ki: 0.12 nM
Simvastatin is a HMG-CoA reductase inhibitor.
HMG-CoA reductase has been found to be the rate-limiting enzyme in the cholesterol biosynthetic pathway and the target of the “statin” class of cholesterol-lowering drugs.
In vitro: Previous study found that simvastatin could inhibit the incorporation of 14C-acetate to 14C-sterol with an IC50 value of 15 nm in cultured Hep G2 cells. In addition, simvastatin was found to be a potent inhibitor of cholesterol synthesis in cultured liver cells, whereas pravastatin inhibited cholesterol synthesis in liver cells only after these cells had been digested by collagenase [1].
In vivo: Animal study showd that rats orally dosed with simvastatin had lower plasma cholesterol levels after 4 days of treatment. At the level of 0.02% of the diet, simvastatin lowered plasma cholesterol levels in rats by 64%. Moreove, in dogs, simvastatin at a daily oral dosage of 8 mg/kg lower levels of plasma cholesterol. At this dosage, simvastatin was slightly more potent than lovastatin and the levels of plasma cholesterol in these dogs returned to pretreatment levels after stopping the treatment [1].
Clinical trial: Previous clinical study found that both atorvastatin and simvastatin had significant PD reduction and RAL gain than placebo. Atorvastatin group showed greater mean PD reduction and mean RAL gain as compared to simvastatin group. Furthermore, atorvastatin group exhibited a significantly greater percentage of radiographic defect depth reduction as compared to simvastatin at 6 and 9 months [2].
References:
[1] Chao, Y. ,Chen, J.S.,Hunt, V.M., et al. Lowering of plasma cholesterol levels in animals by lovastatin and simvastatin. European Journal of Clinical Pharmacology 40, S11-S14 (1991).
[2] S Martande S, Kumari M, Pradeep AR, Pal Singh S, Kumar Suke D. nComparative evaluation of efficacy of subgingivally delivered 1.2% Atorvastatin and 1.2% Simvastatin in the treatment of intrabony defects in chronic periodontitis: a randomized controlled trial. J Dent Res Dent Clin Dent Prospects. 2017 Winter;11(1):18-25.
Physical Appearance | A crystalline solid |
Storage | Store at -20°C |
M.Wt | 460.59 |
Cas No. | 101314-97-0 |
Formula | C25H41NaO6 |
Synonyms | Zocor™ |
Solubility | ≥28.85 mg/mL in DMSO; ≥23.05 mg/mL in EtOH; ≥5.47 mg/mL in H2O with ultrasonic |
SDF | Download SDF |
Canonical SMILES | C[C@H]1C=CC2=C[C@H](C)C[C@H](OC(C(C)(C)CC)=O)[C@]2([H])[C@H]1CC[C@@H](O)C[C@H](CC(O)=O)O.[NaH] |
运输条件 | 蓝冰运输或根据您的需求运输。 |
一般建议 | 不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。 |
质量控制和MSDS
- 批次: